India’s Sun Pharma to Buy Ranbaxy in $3.2 Billion Deal

Sun Pharmaceutical Industries Ltd., India’s largest drugmaker by market value, agreed to buy competitor Ranbaxy Laboratories Ltd. for $3.2 billion from Japan’s Daiichi Sankyo Co., which paid 61 percent more for the company five years ago.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.